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ABSTRACT 
We examined the effect of methylphenidate (Mph) on inhibition and several other 
cognitive abilities in 43 adults with Attention Deficit Hyperactivity Disorder (ADHD) by use 
of Conners’ Continuous Performance Test (CPT) and the Change Task (ChT), an extension of 
the Stop Signal Test (SST). In a double blind, cross-over, placebo controlled study with Mph, 
tests were administered during the third week of individually titrated treatment with Mph 
(maximum dose 1 mg / kg / day) and during the third week of treatment with placebo. We 
established large medication effects for commission errors, standard error of mean reaction 
time, and attentiveness on the CPT, as well as moderate medication effects for mean reaction 
time on the CPT and response re-engagement speed on the ChT. For Stop Signal Reaction 
Time (SSRT) on the ChT, we also established large effects of Mph, but only in a group of 
participants who showed slow SSRTs on placebo. Mph indeed ameliorates inhibition, which 
is the core problem of ADHD, and certain other cognitive abilities in adults with ADHD. 
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For decades, Attention Deficit Hyperactivity Disorder (ADHD) has been thought to 
affect only children. In the last fifteen years or so, however, researchers have established that 
children do not always outgrow their problems with attention, hyperactivity, and impulsivity 
once they reach adulthood. Rather, between 30 to 50% of children with ADHD still meet the 
requirements for the diagnosis in adulthood (Biederman, Mick, & Faraone, 2000; Manuzza, 
Klein, Bessler, Malloy, & LaPadula, 1998; Weiss, Hechtman, Milroy, & Perlman, 1985). This 
has lead to prevalence estimates for the United States of 1-6% of the general population 
(Wender, Wolf, & Wasserstein, 2001). Epidemiologic studies have confirmed these figures in 
adults applying for a driver’s license (Murphy & Barkley, 1996) and in college students 
(Heiligenstein, Conyers, Berns, Miller, & Smith, 1998). 
For a long time, attention problems and hyperactivity have been the most researched 
symptoms of this disorder, but recently impulsivity is increasingly seen as the symptom of 
greatest significance (Taylor, 1998). According to several theories, impulsivity or decreased 
inhibition of behavior even is the central impairment of ADHD (Barkley, 1997; Nigg, 2001; 
Pennington & Ozonoff, 1996; Schachar, Tannock, & Logan, 1993). A possible explanation 
for this shift may be found in the current thought that inhibitory control plays an important 
role in attentional systems, which makes the inattention in ADHD a secondary symptom. As 
Rubia, Oosterlaan, Sergeant, Brandeis and van Leeuwen (1998) stated it: "For example, 
failure to sustain attention may be due to failure to inhibit interfering activities and 
distractibility may be caused by not inhibiting attention to irrelevant information" (p. 25). The 
extensive empirical evidence for deficits in inhibition in children with ADHD is derived from 
studies using different inhibition paradigms, for instance the Stop Signal Test (SST). In a 
meta analysis on SST data in ADHD children, Oosterlaan, Logan, and Sergeant (1998) 
demonstrated that children with ADHD exhibit significantly slower response inhibition times 
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than normal control children. This finding was confirmed in a more recent review of SST 
studies in children (Sergeant, Geurts, & Oosterlaan, 2002). Another paradigm that has often 
been employed in successfully establishing inhibition deficits in children with ADHD is the 
Continuous Performance Test (CPT) (Brandeis et al., 1998; Kerns, McInerney, & Wilde, 
2001) . For reviews of CPT studies in children with ADHD, see Corkum and Siegel (1993), 
Losier, McGrath, and Klein (1996), and Riccio, Waldrop, Reynolds, and Lowe (2001). 
Deficits in inhibition have also been established for adults with ADHD, using both the SST 
(Epstein, Johnson, Indira, & Conners, 2001; Murphy, 2002; Ossmann & Mulligan, 2003; 
Wodushek & Neuman, 2003), and the CPT (Barkley, Grodzinsky, & DuPaul, 1992; Epstein, 
Conners, Sitarenios, & Erhardt, 1998; Epstein et al., 2001; Ossmann & Mulligan, 2003; 
Riccio & Reynolds, 2001; Walker, Shores, Trollor, Lee, & Sachdev, 2000).  
The stimulant methylphenidate (Mph) is one of the most effective and safe 
medications for the treatment of ADHD in children. Approximately 70% of ADHD children 
show a therapeutic response to stimulant medication (Schachter, Pham, King, Langford, & 
Moher, 2001; Wilens & Spencer, 2000). In adults with ADHD, stimulant medication has 
received far less attention than in children. In a recent review, (Wilens, Spencer, & 
Biederman, 2002)  seven Mph studies were mentioned, in which the weighted mean clinical 
response to Mph treatment was 56%. In a recent meta analysis, Faraone, Spencer, Aleardi, 
Pagano, and Biederman (2004) mentioned a mean effect size of 0.9 for six double-blind 
placebo-controlled Mph treatment studies in adults with ADHD. 
Mph has been shown to improve inhibition on several laboratory tasks in children with 
ADHD, such as the CPT (for a review see Losier et al., 1996), and the SST ( Scheres et al., 
2003; Tannock, Schachar, Carr, Chajczyk, & Logan, 1989; Tannock et al., 1995). Information 
on the effect of Mph on inhibition and other cognitive variables tested by the CPT in an adult 
ADHD population is limited. Riordan et al. (1999) established a decrease in visual 
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distractibility with Mph on a CPT. Kuperman et al. (2001) mentioned improvement with Mph 
on attentiveness (one of the signal detection parameters) on a CPT in adults with ADHD, but 
no other parameters were reported. In the only study mentioning an effect of Mph on the 
inhibition parameter of a CPT, the effect was not significant (Gualtieri, Ondrusek, & Finley, 
1985). The effect of Mph on the Change Task (ChT, which is an extended version of the SST) 
in an adult ADHD sample has not been reported thus far. Given the current emphasis on 
inhibition in ADHD, this shortage of studies into the effect of Mph on inhibition in adult 
ADHD is surprising. This is why in the present study, we hypothesized that Mph would 
improve inhibition in adults with ADHD, both on the CPT and the ChT, compared to placebo.  
 
In addition to inhibition, the CPT and the ChT  measure several other variables of 
cognitive functioning. The CPT provides information on processes related to response 
execution (speed and variability), as well as measures that are related to signal detection 
theory (perceptual sensitivity in discriminating targets from non-targets and response style). 
Another interesting feature of the CPT is that stimuli may be presented with different event 
rates, for instance 1, 2 or 4 s between stimuli. This allows for analysis of the involvement of 
behavioral activation in response execution.  An optimal behavioral activation state influences 
motor adjustment, thus affecting response execution (Sanders, 1998). The influence of 
activation levelhas been repeatedly indicated in ADHD in children (Scheres, Oosterlaan, & 
Sergeant, 2001; Sergeant, 2000; Van der Meere, 1996).  
The ChT provides information on similar response execution processes as the CPT. 
Moreover, by instructing subjects to perform another action after they have inhibited their 
prepotent response, it also supplies information on response re-engagement processes. 
Performance on many of these variables has been shown to differ between children with 
ADHD and normal controls (see Losier et al., 1996; Oosterlaan et al., 1998, Riccio et al. 
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2001). Similar information on adults with ADHD is sparse, but available studies indicate that 
they also may show difficulties on some of the abilities mentioned above, such as speed of 
response execution, and attentiveness (Epstein et al., 1998; Epstein et al., 2001).  
Besides its positive effect on the clinical symptoms of ADHD and on inhibition, 
stimulant medication seems to improve specific other cognitive abilities. In children , it has 
been shown to enhance  response speed and accuracy (Klorman et al., 1988; Reid & 
Borkowski, 1984), response variability (Tannock et al., 1995), and response re-engagement 
(Barnett et al., 2001; Berman, Douglas, & Barr, 1999; Kempton et al., 1999; Solanto, 1997; 
Tannock et al., 1995). Studies with Mph in adults with ADHD have suggested that the drug 
may also improve specific cognitive abilities in this group. Kuperman et al. (2001) showed 
advanced response re-engagement abilities and increased fluency with Mph. Other 
researchers have found evidence of increase in working memory ability (Kinsbourne, De 
Quiros, & Tocci Rufo, 2001), motor speed, and processing speed, as well as decreases in 
distractibility (Riordan et al., 1999). 
Our first hypothesis stated that Mph would improve inhibition in adults with ADHD, 
both on the CPT and the ChT, compared to placebo. In order to extend the knowledge of the 
effect of Mph on cognitive abilities, other than inhibition, in adult ADHD, we further 
hypothesized that several cognitive processes (speed of response execution, variability of 
response execution, response re-engagement, attentiveness) measured by the CPT and the 
ChT would improve with Mph, compared to placebo. 
METHOD 
Participants 
Forty-three adults with ADHD between 20 and 55 years of age (M = 38.9 years; SD = 
10.1), 21 men and 22 women, participated in this study. Two of these participants were 
diagnosed with ADHD hyperactive / impulsive subtype, the other 41 were diagnosed with 
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ADHD combined subtype. None of the participants had been treated with Mph prior to this 
study. The average IQ was 100.3 (SD 17.9; minimum 76, maximum 142). The participants 
were either self-referred or referred by other clinicians for assessment of ADHD to an 
outpatient clinic in the Netherlands. Prior to inclusion in the study, participants underwent a 
standardized clinical assessment consisting of a psychiatric evaluation by one of two 
experienced psychiatrists. The following instruments were used: a semi-structured clinical 
diagnostic interview for ADHD and co morbid disorders; several sections from the Dutch 
version of the Diagnostic Interview Schedule (Robins et al., 1995): section L (for the 
retrospective diagnosis of ADHD in childhood), section N (for the retrospective diagnosis of 
oppositional defiant disorder), section O (for the retrospective diagnosis of conduct disorder), 
and section P (for current antisocial personality disorder); the Dutch version of the Composite 
International Diagnostic Interview (CIDI) (version 2.1, lifetime; Robins et al., 1988) for Axis 
I psychiatric disorders; the Dutch version of the International Personality Disorder 
Examination (IPDE) (Loranger, Sartorius, Andreoli, & Berger, 1994) for borderline and 
antisocial personality disorders. For current ADHD-symptoms during the last 6 months, we 
used the Dutch version of the ADHD-Rating Scale (DuPaul, Power, Anastopoulos, & Reid, 
1998), based on the 18 DSM-IV symptom criteria for ADHD. The level of associated 
impairment was assessed using the Dutch version of the Sheehan Disability Scale (SDS) 
(Sheehan, Harnett-Sheehan, & Rai, 1996) and the Global Assessment of Functioning Scale 
(GAF) (APA, 1994). A medical history, a physical examination (blood pressure, pulse and 
weight), and laboratory assessments (complete blood cell count, liver, kidney, thyroid, 
glucose function tests, and electrocardiogram) were also obtained.  
To be given a diagnosis of adult ADHD, subjects had to (1) currently meet at least 5 of 
9 DSM-IV criteria of inattention and / or at least 5 of 9 DSM-IV criteria of hyperactivity / 
impulsivity (based on the ADHD Rating Scale), (2) meet at least 6 of 9 DSM-IV criteria of 
Does Mph improve inhibition? 8
inattention and / or at least 6 of 9 DSM-IV criteria of hyperactivity / impulsivity in childhood 
(based on the DIS- section L), (3) describe a chronic persisting course of ADHD symptoms 
from childhood to adulthood, and (4) endorse a moderate to severe level of impairment 
attributed to ADHD symptoms. The cutoff point of 5 of 9 hyperactive / impulsive symptoms 
and / or 5 of 9 inattention symptoms for adult diagnosis of ADHD is in line with previous 
research (Biederman et al., 2000; Murphy & Barkley, 1996). In order to obtain information 
about lifetime ADHD symptoms and impairment, the participant, the partner (if available), 
and (if possible) the parents were interviewed. Information on school reports was examined in 
order to substantiate the diagnosis in childhood. We estimated the IQ of participants based on 
four subtests of the Dutch version of the Wechsler Adult Intelligence Scale-III: Vocabulary, 
Arithmetic, Block Design, and Picture Arrangement. The reliability of this short form has not 
been established for the WAIS-III yet, but for the WAIS-R these four tests have been found to 
estimate Full Scale IQ with greater accuracy than other variations (Boone, 1990). Data for 
several diagnostic measures are provided in Table 1. 
------------------------------------------- 
Insert Table 1 about here 
------------------------------------------- 
Subjects with co morbid psychiatric disorders were included, unless these disorders 
required to be treated first (for instance severe depression or anxiety) or when treatment with 
Mph was contra-indicated (for instance with hypertension). The number of eligible 
participants was 108. Before study entry, 15 people withdrew consent for the trial. We 
excluded 41 participants: four with clinically significant medical conditions, one with 
abnormal baseline laboratory values, seven with other psychiatric conditions that required to 
be treated first, 11 because of current use of psychotropics, and 18 because of prior use of 
Mph or amphetamines. Other exclusion criteria were: a history of tic disorders, IQ below 75, 
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any neurological condition that could interfere with a diagnosis of ADHD (such as 
concussion, meningitis, traumatic brain injury), suicidal behavior, psychosis, mania, physical 
aggression, and pregnancy or nursing. No participants had to be excluded based on these 
criteria. After study entry and full diagnostic assessment, seven participants were ineligible: 
five due to current substance abuse, one due to hypertension, and one due to severe 
depression that urgently required treatment. In the end, 45 participants were randomized and 
completed the trial. Data of two participants could not be used for the neuropsychological part 
of the study due to incompletion (n = 1) and positive urine screening for opiates (n = 1). The 
study was approved by the local Medical Ethical Committee, and all subjects completed a 
written informed consent form before inclusion in the study. 
Materials 
Continuous Performance Test 
Computerized CPTs are often used to study vigilance in ADHD populations. Most 
CPTs require a subject to press a key in response to a target stimulus (for instance the letter 
X, or the letter A followed by an X) and to ignore non-target stimuli. The version used in this 
study is the Conners’ Continuous Performance Test  (Conners, 1995), which differs from 
traditional (X and A-X) CPT paradigms (Rosvold, Mirsky, Sarason, Bransome, & Beck, 
1956). In Conners’ CPT, the response required for the critical signal of X is to withhold a 
discrete and repetitive motor response, rather than to respond to it. For all other stimuli, a 
response of pressing the space bar is required. This means that omission errors indicate a 
failure to execute the required response, whereas commission errors suggest an inability to 
inhibit the prepotent response. Next to sustained attention, the main measurement objective of 
traditional CPTs, the  Conners’ CPT may invoke executive or controlled attention(Ballard, 
2001). As far as we know, this version of the test has only been used in one study with Mph 
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in an adult ADHD population (Kuperman et al., 2001). However, this study only reported 
medication effects on the dependent variable attentiveness (d’). 
The task consisted of six blocks of 60 trials. Each block contained three sub-blocks of 
20 trials each. Stimuli presented were letters of approximately 1 inch in size. Ten percent of 
stimuli in each block were Xs, with a total of 36 Xs for the entire test. Other letters presented 
were A, B, C, D, E, F, H, I, L, M, N, O, T, Y, and Z. For each block, the sub-blocks had 
different inter-stimulus intervals (ISIs): 1, 2, or 4 s. The order of sub-blocks randomly varied 
between blocks. Each letter was displayed for 250 ms. The most often reported (and therefore 
also chosen for this study) dependent variables are: 1) the number of commission errors, 
measuring inhibitive behavior (high error rates indicate poor inhibitive control), 2) mean 
reaction time for hits (to measure the latency of the response execution process), 3) the 
standard error of the mean hit reaction time (an indication of the consistency with which 
respondents can focus their attention), 4) attentiveness (d’), which is an indication of the 
ability to discriminate between targets and non-targets, and 5) risk taking (β) (an indication of 
a person’s response style: high values point to cautious response styles, whereas low values 
suggest more risk taking). Omission errors were not analyzed for this study, since the 
participants made hardly any errors of this type (M (placebo) = 2.4; M (Mph) = 1.8). 
Change Task 
The Change Task (ChT) (Logan & Burkell, 1986) is an extension of the Stop Signal 
Test (SST) (Logan, Cowan, & Davis, 1984). The SST measures response execution and 
response inhibition processes, while the extended ChT is also used to investigate response re-
engagement. To our knowledge, this test has not been used previously in any studies with 
adults with ADHD.  
The ChT used in this study consisted of go trials and stop trials. For both types of 
trials, an aeroplane was presented for 1000 ms at either the left or the right side of the screen. 
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Immediately before stimulus onset, a fixation point (500 ms in duration) appeared at the 
center of the screen. A right sided stimulus required subjects to press the right response button 
as quickly as possible. If the aeroplane was presented on the left, the left response button had 
to be pressed. Subjects were instructed to use the index and middle fingers of their dominant 
hand. Between trials the screen turned blank for 1500 ms. Stop trials were identical to go 
trials, but in addition a stop signal (a 1000 Hz tone, 50 ms in duration) was presented through 
stereo earphones. When a stop signal was presented, participants were to withhold their 
response (i.e., not to press any button with their dominant hand). In addition, they had to press 
a different button with their non-dominant thumb as quickly as possible. This is the Change 
Response, a measure of response re-engagement. Seventy-five percent of trials were go-trials, 
and 25% were stop trials. Trials were presented in blocks of 64 trials. Stop signals were 
presented at predetermined intervals before the subject’s expected response. This provides the 
opportunity to ascertain the ability to inhibit a response at different points in the response 
execution process. The shorter the time interval between the stop signal and the expected 
response, the more difficult it becomes to inhibit this response. Intervals between stop signal 
and expected response were set at 50 ms, 200 ms, 350 ms, or 500 ms with each interval 
occurring on 25% of the stop trials. The expected moment of response was based on the mean 
reaction time in the previous block. The task started with three practice blocks to familiarize 
participants with the paradigm. In the first block only go trials were presented (primary task). 
In the second practice block, 25% of trials were stop trials, which only required inhibition of 
response. In the last practice block, stop signals required both response inhibition and 
response re-engagement. After practice, participants were administered four experimental 
blocks of 64 trials each. Standardized instructions pressed participants not to wait for the stop 
signal, but to continue pressing the buttons as quickly as they could. 
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The main dependent measure for this task is Stop Signal Reaction Time (SSRT). This 
is an estimate of the time it takes before the inhibition process is engaged. SSRT cannot be 
measured directly, but it can be estimated using the Race Model (Logan, 1994). According to 
the Race Model response inhibition depends on the outcomes of a race between two sets of 
processes that operate independently. One set starts with the onset of the go-stimulus (the 
aero plane at the left or right side of the screen) and results in the activation and execution of 
the response, whereas the other set starts with the onset of the stop signal and results in the 
onset of the inhibitory process (Logan & Cowan, 1984). The response is made or withheld, 
depending on which set of processes wins the race. In practice, SSRT is calculated as follows: 
first, reaction times on go-trials are rank ordered on a time axis. Then, the nth reaction time is 
picked, whereby n is defined by the product of the number of reaction times in the distribution 
and the probability of responding given a stop signal. This gives an estimate for the time at 
which the inhibition process runs to completion, relative to the onset of the primary task 
stimulus. Third, the delay between onset of the primary task stimulus and the stop signal is 
subtracted from the nth reaction time and thus SSRT is estimated. For more detailed 
information on the calculation of SSRT, the reader is referred to Logan et al. (1984). In 
addition to SSRT, other dependent variables included in the analyses were: 1) the mean 
reaction time on go-trials of the primary task (measuring latency of response execution), 2) 
the standard deviation of the reaction times on go-trials of the primary task (measuring 
variability in the latency of the response execution process), 3) the mean reaction time on the 
Change Response of the task (an indication of the speed of the response re-engagement 
process), and 4) the standard deviation of the Change Response latencies (to measure 
variability in the speed of the response re-engagement process). Another measure often 
reported in research using the SST is the slope of inhibition function. Recently however, 
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Band, Van der Molen, and Logan (2002) indicated that this variable is not a reliable indicator 
of differences in inhibition. Therefore, this variable was not analyzed in the current study. 
Procedure 
Participants entered a double blind, placebo controlled, cross over trial of Mph. The 
design of this trial and clinical outcomes are described in detail elsewhere (see Kooij et al., in 
press). We designed the trial based on the medication study by Spencer et al. (1995). There 
were two 3-week treatment periods for each participant, one period of three weeks for Mph 
and one period of three weeks for placebo, with 1 week of washout in between.  
The order of treatment (Mph-placebo or placebo-Mph) was randomized. Weekly 
supplies of Mph (10 mg per tablet) or placebo were prepared and dispensed by the hospital 
pharmacy in identically appearing tablets. Placebo tablets contained only a base granulate. 
Mph tablets contained only Mph granulate. Medication was prescribed in four times or five 
times a day dosing, depending on whether rebound occurred. Study medication was titrated 
up from low to high doses, to avoid exposure to high initial doses of active medication and to 
minimize side effects. Participants started with 0.5 mg / kg per day in week 1, followed by 
0.75 mg / kg per day in week 2, and up to 1.0 mg / kg per day in week 3, unless adverse 
effects emerged. A dose of 1.0 mg / kg has been shown to be a reasonable upper limit dosage 
for clinical purposes (Sachdev & Trollor, 2000). To control for possible substance use during 
the trial, patients were asked unannounced twice to hand over a urine sample.  
Repeated administrations of the inhibition tasks described above were obtained in 
week 3 (highest dose of Mph, or placebo) and in week 7 (highest dose of Mph, or placebo). 
Testing started one hour and fifteen minutes after tablet intake. Mph peak concentrations in 
the brain are reached after approximately 60 minutes (Volkow et al., 1995). Maximal 
therapeutic effects are reached within approximately 2 hours after ingestion (Swanson, 
McBurnett, Christian, & Wigal, 1995; Wilens, Biederman, Spencer, & Prince, 1995). The 
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behavioral half-life of the drug is approximately 3 hours (Solanto & Conners, 1982). 
Administration of the inhibition battery took approximately 1 hour, so testing was completed 
between the moment of peak Mph levels in the brain and the behavioral half-life value.  
Besides two treatment orders (Mph-placebo or placebo-Mph), inhibition tasks were 
also administered in two different test orders (CPT-ChT or ChT-CPT), to be able to control 
for possible effects of fatigue and for effects of declining medication efficacy. 
Statistical Approach 
In order to check whether treatment order or test order interacted with the effect of 
treatment condition, separate MANOVAs were conducted for the dependent variables of the 
CPT and the ChT, with treatment condition (Mph or placebo) as within subject factor and 
treatment order (Mph-plac or plac-Mph) and test order (CPT-ChT or ChT-CPT) as between 
subjects factors. If no overall interactions between treatment condition and treatment order or 
test order were found, the effects of medication on the dependent variables were further 
analyzed with ANOVAs with treatment condition as within subject factor. If, however, 
overall interactions between treatment condition and treatment order or test order were 
significant, univariate cross-over results were interpreted only for those variables that did not 
show an interaction. For variables that did show a univariate interaction, only data from the 
parallel trial (the first three weeks of treatment) were analyzed in an ANOVA with treatment 
condition as between subjects factor. Our alpha level was set at .05.  
The data of one participant were excluded from the analyses for the ChT, because 
mean scores on several dependent variables deviated more than 1.5 times the interquartile 
range from the 25th or 75th percentile. 
RESULTS 
Group characteristics for the two treatment order groups are shown in Table 2. 
Statistical analyses confirmed that there were no differences between the two groups in 
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number of participants, gender distribution, age, IQ, absolute dose (in mg / day), or relative 
dose (in mg / kg / day) of Mph at time of testing. 
------------------------------------------- 
Insert Table 2 about here 
------------------------------------------- 
Main analyses 
Continuous Performance Test 
There was no interaction between treatment condition and treatment order (Wilks’ Λ = 
.77, F(5, 35) = 2.12, p = .086), nor between treatment condition and test order (Wilks’ Λ = 
.93, F(5, 35) = .49, p = .779). Therefore, the effects of treatment condition on the dependent 
variables of the CPT were further analyzed without taking either treatment order or test order 
into account. A MANOVA with treatment condition as within subject factor showed an 
overall significant effect of treatment (Wilks’ Λ = .60, F(5, 38) = 4.98, p = .001, η2 = .40). 
Separate ANOVAs with treatment condition as within subject factor (see Table 3 for means 
and standard deviations) revealed a significant decrease of commission errors with Mph 
(F(1,42) = 10.88, p = .002). The accompanying effect size (η2 = .21) was large (Cohen, 
1988). We also established a significant increase in mean reaction time with medication 
(F(1,42) = 5.10, p = .029) with a medium effect size (η2 = .11). Standard error of hits 
significantly decreased with Mph (F(1,42) = 7.15, p = .011), with a large effect size (η2 = 
.15). There was a significant improvement in attentiveness (d’) (F(1,42) = 8.17, p = .007). 
The effect size of the latter increase was large (η2 = .16). The only CPT variable that did not 
show a change with medication was risk taking (β) (F(1,42) = .43, p = .837, η2 = .00). 
------------------------------------------- 
Insert Table 3 about here 
------------------------------------------- 
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CPT – Analyses of ISI 
For several variables (commission errors, mean hit reaction time, and standard error of 
reaction time) of the CPT, separate data are available for the three different ISIs. These 
variables were analyzed in ANOVAs with two within subject factors: ISI (three levels: 1, 2, 
or 4s) and treatment condition with two levels, to check if Mph has a different effect for 
different ISIs. Because of possible violations of the sphericity assumption, degrees of freedom 
and related p-values were corrected according to the Greenhouse-Geisser method. For 
commission errors, there was no significant interaction between treatment condition and ISI 
(F(1.89, 79.21) = .54, p = .940, η2 = .00). Mph  did not change the number of commission 
errors made over the different ISIs. As can be seen in Figure 1, there was a significant 
interaction effect of ISI and treatment condition for mean hit reaction time (F(1.75, 73.53) = 
5.15, p = .011, η2 = .11). Post hoc paired samples t-tests revealed that the difference between 
placebo and Mph was significant only for an ISI of 1 s (t(42) = 3.95, p = .000). Mph 
significantly slowed down the mean hit reaction time for an ISI of 1s. 
------------------------------------------- 
Insert Figure 1 about here 
------------------------------------------- 
Figure 2 displays the standard error of mean hit reaction time. For this variable we 
established a significant interaction of ISI and treatment condition (F(1.88, 79.06) = 5.07, p = 
.010, η2 = .11). Post hoc paired samples t-tests showed the effect of Mph to be significant 
only for an ISI of 4 s (t(42) = -3.14, p = .003). So Mph lead to less variability in responding at 
a large ISI. 
------------------------------------------- 
Insert Figure 2 about here 
------------------------------------------- 
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Change Task 
There was no significant interaction between medication treatment condition and test 
order (Wilks’ Λ = .91, F(5, 34) = .67, p = .628). Therefore, the effects of medication for this 
test were further analyzed without taking test order into account. There was, however, a 
significant interaction between treatment condition and treatment order (Wilks’ Λ = .51, F(5, 
34) = 6.60, p = .000). Univariate tests revealed significant interactions of treatment condition 
and treatment order for mean reaction time (F(1, 38) = 12.20, p = .001), and standard 
deviation of reaction times (F(1, 38) = 21.00, p = .000). Apparently, for these variables it 
made a difference whether Mph or placebo was administered first. For these variables, main 
effects of treatment condition were therefore analyzed only for the parallel trial (after three 
weeks of treatment, during the highest dose of Mph or placebo).  
The variables that did not show univariate interactions of treatment order and 
treatment condition were further analyzed with ANOVAs with treatment condition as within 
subject factor (see Table 4 for means and standard deviations). For SSRT, no decrease with 
medication was found (F(1, 41) = 3.08, p = .087, η2 = .07). Inhibition as measured by this 
variable, did not  improve with Mph. A significant decrease in mean reaction time on the 
Change Response with Mph was established (F(1, 41) = 4.84, p = .033). The accompanying 
effect size was medium (η2 = .11). This indicates an improvement in response re-engagement 
with Mph. The standard deviation of these Change Response reaction times was not different 
under medication or placebo (F(1, 41) = .26, p = .615, η2 = .01).  
For the two variables that showed significant interactions between treatment order and 
treatment condition, data for the first point of measurement (after three weeks) were 
compared in an ANOVA with treatment condition as a between subjects factor (see Table 4 
for means and standard deviations). There was no significant effect of Mph on mean reaction 
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time (F(1, 40) = .91, p = .346, η2 = .02). A marginally significant decrease with Mph could be 
established for the standard deviation of reaction times (F(1, 40) = 4.02, p = .052, η2 = .09).  
------------------------------------------- 
Insert Table 4 about here 
------------------------------------------- 
Post-hoc analyses 
Several exploratory analyses were conducted to characterize the results more 
completely. In order for a medication effect to be not only statistically but also clinically 
significant, one would like medication to normalize scores on dependent variables. To check 
whether this was the case for our sample, we compared the mean of our medicated ADHD 
group with the group mean of a normal control sample from another study for the variable 
that showed the largest effect size in our study: commission errors on the CPT. The normal 
control participants in a study by Murphy, Barkley, and Bush (2001) carried out the exact 
same version of the CPT as our ADHD participants. A one sample t-test showed no 
differences (t(42) = -.28, p =.78) between the mean number of commission errors of our 
medicated ADHD sample (M = 10.7) and the mean of the normal control sample (n = 64, M = 
11), indicating a similar level of inhibition in both groups. When we compared our ADHD 
sample off medication (placebo scores) and the same normal control group, the difference was 
significant (t(42) = 2.23, p =.03): the ADHD group showed worse inhibition capacities than 
the normal control group from Murphy et al. 
It is possible that medication effects are found only when there is room for 
improvement. To check this possibility, we compared medication effects (difference scores 
between placebo and Mph) on CPT commissions and on ChT SSRT for participants with 
placebo scores below and above the means of these variables. For CPT commissions, the 
group (n = 18) who made a larger number of commission errors (compared to the mean 
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placebo commission score) improved significantly more with Mph than the group who made 
a smaller number of errors (n = 25; again compared to the mean placebo score) (F(1, 41) = 
8.21, p = .007,  η2 = .17). For SSRT on the ChT, the effect of high versus low placebo scores 
was even larger. Participants who showed slower than average SSRTs on placebo (n = 22) 
improved much more with medication than participants who responded faster than average to 
begin with (n = 20) (F(1, 40) = 25.15, p = .000,  η2 = .39). This latter result is in contrast with 
the non-significant results in the total sample. Apparently, Mph does significantly improve 
inhibition as measured by the ChT in participants who show low scores on SSRT to begin 
with. 
To check what the predictive value of improvement on cognitive tests is for clinical 
respondership, we conducted a discriminant analysis to determine whether the difference 
between placebo and medication scores for the two most often reported dependent variables 
for our neuropsychological tests (commission errors and SSRT) could predict clinical 
respondership. Clinical respondership for each participant was determined according to Kooij 
et al. (in press), who defined clinical response as a decrease of at least two points on the 
investigator based Clinical Global Impression Scale for ADHD over the total treatment period 
(three weeks), and a 30% or more symptom reduction on the selfreported ADHD Rating 
Scale.The overall Wilks’ lambda was significant for change in commission errors on the CPT 
(Λ = .79, χ2(2, N = 43) = 9.15, p = .010), but not for the SSRT of the ChT. Only the 
significant discriminant function was interpreted. Clinical respondership could be correctly 
classified based on decrease of commission errors in 79% of the cases. Ten of 16 responders 
were correctly classified, leading to a sensitivity of 63%. Twenty-three of 26 non-responders 
were correctly classified as such, indicating a specificity of 89%. Positive predictive power of 
the decrease in commission errors on clinical respondership was 78%, negative predictive 
power was 79%. In order to take into account chance agreement, we computed a kappa 
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coefficient and obtained a value of .53, which can be considered moderate (Landis & Koch, 
1977).  
Finally, we performed a partial correlation analysis to check whether the amount of 
commission errors on the CPT during Mph was related to several clinical variables rather than 
to Mph, when placebo-commission errors were partialed out. There were no significant 
correlations between Mph-commission errors and any of the following variables: severity of 
ADHD (number of DSM-IV symptoms; r = -.14, p = .37), relative Mph dose at endpoint (in 
mg / kg; r = -.03, p = .86), absolute dose at endpoint (mg; r = -.00, p = .99), co morbid anxiety 
disorder (r = .27, p = .09), number of co morbid disorders (r = .28, p = .07), or IQ (r = .06, p 
= .71). 
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DISCUSSION 
The present study was designed to examine the effects of Mph on inhibition and other 
cognitive measures in a sample of adults with ADHD. The group analyses indicated rather 
strong effects of Mph on inhibition and response measures on the CPT. However, no group 
effect on inhibition and only modest effects on other response measures were found on the 
ChT. 
With respect to the CPT, the inhibition results confirm our hypothesis and they are in 
line with previous research in ADHD children (Losier, 1996). For adults, very few medication 
studies of commission errors on the CPT are available. Results by Gualtieri et al. (1985) 
indicate a decrease in commission errors on a CPT, although this decrease just fell short of 
significance. However, our study provides more reliable changes, since Gualtieri and 
colleagues tested after a single dose of Mph, rather than an entire week of medication. When 
breaking down commission errors into number of errors for different ISIs, the results indicate 
that the commission errors occur independently of event rate, both in the placebo and the Mph 
condition. This result may underline the suggestion that inhibition is not influenced by a 
behavioral activation level (Sergeant, Oosterlaan, & Van der Meere, 1999). When we 
compared a subgroup of our participants whose placebo score on commission errors was 
worse than that of a normal control group from the study by Murphy et al. (2001), the effect 
of Mph on commission errors was even larger. 
We hypothesized the effect of Mph on SSRT of the ChT to be stronger than what we 
actually found. Our finding cannot be compared with adult ADHD data, since the effect of 
Mph on SSRT has not been studied in this population before. In children with ADHD, three 
studies reported substantial faster SSRTs with Mph (Scheres et al., 2003; Tannock et al., 
1989, 1995), while Overtoom and colleagues (in press) did not observe changes in SSRT with 
Mph. Post hoc analyses of our data indicated that Mph does induce a large improvement in 
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SSRT for a subgroup of our participants whose SSRT on placebo was slower (indicating 
worse inhibition) that the mean placebo SSRT score of the entire group. However, this does 
not explain why we did not find an improvement of SSRT in the entire ADHD group, 
whereas we did find a decrease of commission errors on the CPT. Possible explanations for 
this deviance will be explored later in this discussion. 
Other cognitive processes measured by the two paradigms used in this study include 
latency and variability of response execution processes (mean reaction time and variability in 
reaction times on both CPT and ChT), attentiveness (d’; CPT), response style (β; CPT) and 
response re-engagement (MRT and SD; only in the ChT). Reaction times became slower with 
medication on the CPT. This is in contrast with research in children (Klorman, Brumaghim, 
Fitzpatrick, & Borgstedt, 1991; Riccio et al., 2001) and adults with ADHD (Riordan et al., 
1999), in which faster rather than slower MRTs with medication have been established. When 
breaking down the MRT effect on the CPT into effects for different ISIs, we found the 
expected slowing of MRT with longer ISIs (ADHD subjects have been shown before to show 
slower RTs with longer ISIs, see Scheres et al. 2001). Only with the shortest ISI, however, 
did medication slow RT significantly. The overall slowing of MRT with medication seems to 
be best and solely explained by aslower  MRT with the shortest ISI. Apparently, Mph allows 
ADHD participants to respond less impulsively at short ISIs. This is in accordance with 
research by Berman et al. (1999), which showed that Mph slowed down RT only on the most 
difficult, high load test conditions (the shortest ISI can be considered to be a high load). This 
result implies that Mph improves self-regulatory abilities, as suggested by Douglas (1988, 
1999). 
We also found that treatment with Mph decreased variability of mean reaction times 
on both the CPT and the ChT. This is in agreement with earlier studies in children with 
ADHD (Tannock et al., 1989, 1995). No comparable research is available for adults with 
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ADHD. The overall decrease of variability in reaction times on the CPT could be broken 
down into different effects for different ISIs. Mph effects on variability seem to be larger for 
longer ISIs. This is propitious, since ADHD is known to lead to increasing variability in 
response execution with slow event rates (i.e., longer ISIs) (Scheres et al., 2001; Van der 
Meere, Shalev, Borger, & Gross-Tsur, 1995). Apparently Mph increased the behavioral 
activation level (Sanders, 1998), which allowed participants  to respond more evenly. 
Response re-engagement on the ChT (the Change Response) was sped up by Mph. 
This concurs with a recent study, showing that Mph enhanced task switching performance in 
ADHD children (Kramer, Cepeda, and Cepeda, 2001), and it is in line with earlier findings on 
the effect of Mph on the Change Response (see the Materials section for an explanation of the 
Change Response) in children with ADHD (Tannock, 1995). No data on the effect of Mph 
adult performance on this variable are available. Variability in response re-engagement 
reaction times was not affected by medication. No previous studies have reported on this 
measure in adults with ADHD, but based on decreased response variability in primary 
reaction times with Mph, one might expect this variability on a secondary task to decrease as 
well. This was indeed found in a child ADHD sample (Tannock, 1995). Possible explanations 
for this divergence will be explored later on in the discussion. 
Attentiveness (d’) on the CPT increased with medication, which is in keeping with 
medication studies in children with ADHD (Losier, 1996), and with studies in adults with 
ADHD (Kuperman et al., 2001). Risk taking (β) did not change with Mph treatment, which 
also in line with previous studies in children (Losier, 1996). In adults with ADHD, the effect 
of Mph on this variable has not been reported before. It should be mentioned, however, that 
the standard deviation of this parameter was about as large as the mean, which makes 
interpreting any results with this variable difficult. It also raises questions about the accuracy 
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of the calculation of this measure by the scoring program. Similar observations were made by 
Epstein et al. (1998). 
Exploratory analyses indicated that Mph may indeed normalize the number of 
commission errors made on the CPT by ADHD participants to the level of a normal control 
group. We only compared data for one dependent variable, so we cannot generalize this result 
to other cognitive abilities, but it is a promising result for clinical practice. Future research 
should compare other processes, preferably with a normal control group recruited especially 
for that study, since the normal control sample in the study by Murphy et al. (2001) was  
younger than our ADHD sample. If other variables of the CPT also normalize with Mph, this 
may render this test suitable for quantitatively establishing the effect of Mph on an individual 
level. This would be a valuable contribution to the entire ADHD population (both children 
and adults), since changes in symptoms are now indicated by either observers, who may not 
always be as objective as necessary, or by patients themselves, who may not have an accurate 
perception of these changes (Barkley, Fisher, Smallish, & Fletcher, 2002). The clinical value 
of a decrease in commission errors is also substantiated by the receiver operating 
characteristic analyses we performed. We ascertained that the overall predictive value of the 
difference between placebo and medication commission errors on the CPT was 79%. The 
related sensitivity of 63% indicates that the decrease in commission errors from placebo to 
Mph has a moderate predictive value for clinical respondership. The specificity of this 
decrease seems to be better: 88% of participants who did not show a large decrease, were not 
clinical responders. Elwood (1993) argues that a more accurate measure of utility of 
neuropsychological variables is the positive and negative predictive power. Positive 
predictive power for the change in commission errors indicates that of those participants who 
showed large decreases in this type of errors, 78% were responders. Conversely, 79% of 
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participants who showed a smaller decrease of commission errors, were correctly classified as 
non-responders.  
We found no significant correlations between medication commission errors on the 
CPT and several clinical variables, while partialing out placebo commission errors. This 
indicates that improvement in commission errors with medication is not influenced to a 
significant extent by the severity of ADHD, the administered dose of Mph (either relative or 
absolute), the number of co morbid disorders, co morbid anxiety disorder, and IQ. Of course 
these analyses are only superficial, and no definitive conclusions can be drawn based upon 
these results. Larger groups of participants would allow for more substantial analyses into 
these issues. However, the results do suggest that the effect of Mph on commission errors on 
the CPT takes place rather independently of the variables mentioned. For all the exploratory 
analyses, it should be stressed that only a few variables were used in the analyses. So 
exploratory results only play up to future research: of course other variables and other tests 
should be evaluated before firm conclusions can be drawn. 
All in all, many of the effects found in our study are in accordance with previous Mph 
studies with either adults with ADHD and / or children with ADHD. However, two deviant 
results were established. The first deviant result is lack of reduced variability in the reaction 
times on the Change Response. This may be due to large within group variability for this 
variable. The decrease in mean reaction time of the Change Response is significant, while the 
decrease in the standard deviation of reaction times is not. Proportionally, however, these 
decreases are similar for both variables. The within group variance is, again proportionally 
seen, much larger for the standard deviation of mean reaction times on the Change Response 
than for the mean reaction time of the Change Response, which could easily lead to lack of 
significant ANOVA results. 
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The second and main divergent result is a lack of robust decreases in SSRT on the 
ChT for the total ADHD group. Several explanations can be given for the this deviation. A 
possible explanation can be found in the work of Tannock and colleagues (1995), who found 
an inverse U-shaped dose-response curve for SSRT in a ChT: Mph induced the largest 
reduction in SSRT with a medium dose (0.6 mg / kg). Decreases in SSRT were not 
established  with low (0.3 mg / kg) nor with high (0.9 mg / kg) doses. In our study, the mean 
relative dose (0.9 mg / kg) was similar to the high dose in Tannock’s study. Future research 
with different doses of Mph should prove whether medium doses improve inhibition on the 
ChT in adults with ADHD. 
Another elucidation for our absence of a robust reduction in SSRT may be offered by 
Scheres et al. (2003), who indicated that a Stop Task with a tracking mechanism may be more 
sensitive to medication effects than the version with a fixed intervals method, used here. The 
version with a tracking mechanism assures a constant inhibition probability of 50%, which 
provides the most reliable estimation of SSRT (Band et al., 2002). When the percentage 
inhibition is lower or higher than 50%, estimations of SSRT may be underestimated or 
overestimated, respectively. The results of a recent study (Aron, Dowson, Sahakian, & 
Robbins, 2003) indicate that Mph may indeed improve inhibition as measured with a tracking 
version of the SST in adults with ADHD.Our data evoke the important question of why Mph 
has a robust effect on commission errors on the CPT, and not on SSRT on the ChT, while 
both variables are supposed to measure inhibition. It may be the case that the two 
operationalizations of response inhibition actually tap into slightly different abilities. This 
suggestion is underpinned by the low correlation between SSRT and commission errors (r = 
.21). The nature of the two tasks also indicates several differences. First of all, in the CPT, the 
signal to withhold a response is given before the actual response is started up, while the ChT 
requires withholding a response that has already commenced in a large part of the trials. 
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Secondly, there is a difference in the percentage of targets in both tasks. In the ChT, 25% of 
trials require withholding a response, while this is only called for in 10% of the trials in the 
CPT. This discrepancy may cause differences in the state of arousal that participants are in 
while performing both tasks, which may influence the effect of Mph on both tasks. 
A third difference between the two tasks is the nature of the stop signal. In the CPT, 
this signal is visual, and similar to the target signals. In the ChT, the stop signal is auditory. It 
has been suggested that children with ADHD have particular difficulties with processing 
information in the auditory modality (Riccio, Hynd, Cohen, Hall, & Molt, 1994). If this is 
also the case in adult ADHD, this factor may interfere with improvement on the ChT with 
medication.  
Yet another, important difference can be found in the level of difficulty of both tasks. 
Inhibition on the ChT requires withholding a response while being in a more or less alerted 
state. The participant is anticipating a plane on either side of the screen and has to actually 
pay continuous attention in order to give the correct response in this two-choice reaction time 
task. With the CPT, it seems easier to drift into a semi-alert state of attention, since this is a 
simple go- no go task. Every stimulus requires the same response, i.e., pressing the space bar. 
Besides this difference in difficulty, the ChT requires response re-engagement after inhibition 
of the primary response. This also makes the inhibition process in this task a different, and 
more difficult process from inhibition in the CPT. Tannock et al. (1995) have indeed found 
smaller Mph effects on SSRT in the more demanding ChT, compared to the easier SST (used 
in their 1989 study). Increased cognitive load may reduce the magnitude of the effect of 
stimulants. This is in line with previous research, where performance decrements at high 
doses have been found on tasks that were complex, or on the most difficult level of tasks 
(Berman et al., 1999; Douglas, 1988; Tannock & Schachar, 1992). This underscores the 
importance of studying the effects of different doses in adults with ADHD, since the optimal 
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dose for ameliorating behavioral symptoms, may not necessarily the most effective dose for 
several cognitive abilities (Cantwell & Swanson, 1997). 
We tried to establish the effect of Mph on inhibition in adults with ADHD. Although 
our data suggest positive effects of the drug on inhibition, we did not test whether this holds 
for all forms of inhibition. As noted by Evenden (1999), “there is not one unitary impulsivity 
or only one type of impulsive behavior” (p. 348). Different researchers have proposed 
different taxonomies for subdividing inhibition (Barkley, 1997; Nigg, 2001). So further 
studies are necessary to determine  which form of inhibition is improved by Mph  and to 
better operationalize  different forms of inhibition.  
In sum, current findings showed that, in adults with ADHD, Mph has large beneficial 
effects on inhibition as measured by the CPT. It also has a large effect on inhibition as 
measured by the ChT, but only in those subjects who show slow inhibition times off-
medication. In addition to improving inhibition, Mph decreases variability in response 
execution processes on  the CPT, and it improves the ability to distinguish signal from noise 
on the CPT. Finally, Mph has a positive effect on response re-engagement, as measured by 
the ChT. Thus, Mph does not only effectively ameliorate clinical symptoms in an adult 
ADHD population, as shown by several researchers (for a review, see Wilens et al., 2002), 
but its positive effects can also be demonstrated on several cognitive processes important in 
daily life. 
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Table 1  
Group Characteristics on Diagnostic Measures 
Measure value M (SD) 
Number of currently endorsed DSM-IV criteria for ADHD 15.5 (2.1) 
Number of DSM-IV criteria for ADHD endorsed in childhood (DIS-L) 12.0 (4.1) 
Sheehan Disability Scale (minimum 0, maximum 30) 22.8 (3.3) 
Global Assessment of Functioning  
(minimum 0, maximum 100) *
57.3 (6.1) 
Axis I co morbid disorders (CIDI Lifetime) 
 any co morbid disorder 
 multiple co morbid disorders ( ≥ 2) 
 any anxiety disorder 






Axis II co morbid disorders  
 Antisocial Personality Disorder (IPDE) 




Note. CIDI = Composite International Diagnostic Interview; IPDE = International Personality 
Disorder Examination. 
* Scores above 70 indicate normal functioning. 
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Table 2 
Characteristics of Two Treatment Order Groups and of Total Group 
 Mph – Plac 
(n = 24) 
Plac – Mph 
(n = 19) 
Total group 
(N = 43) 
men / women 14 / 10 8 / 11 22 / 21 
age (M, SD) 38.5 (9.9) 38.3 (10.6) 38.4 (10.1) 
IQ (M, SD) 100.3 (17.6) 100.2 (18.7) 100.3 (17.9) 
dose (mg)  
(M, SD) 
74.8 (15.6) 65.3 (16.9) 70.6 (16.7) 
dose (mg / kg) 
(M, SD) 
.97  (.13) .88 (.23) .93 (.18) 
Note. Mph = methylphenidate; Plac = placebo. 
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Table 3 
Descriptives and Statistics for Continuous Performance Test Variables 
Variable Placebo Mph F p η2
mean hit reaction 
time  
(M, SD) 
333.5 (48.7) 342.6 (48.7) 5.10 .029 .11 
standard error 
(M, SD) 
6.0 (3.3) 4.9 (2.4) 7.15 .011 .15 
commissions 
(M, SD) 
13.6 (7.6) 10.7 (7.2) 10.88 .002 .21 
attentiveness (d’) 
(M, SD) 
3.1 (0.9) 3.4 (0.9) 8.17 .007 .16 
risk taking (β) 
(M, SD) 
.06 (.05) .07 (.06) .43 .837 .00 
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Table 4 
Descriptives and Statistics for Change Task Variables 
Variable Placebo Mph F p η2
SSRT (M, SD) 220.0 (56.4) 202.3 (50.5) 3.08 .087 .07 
MRT (M, SD)* 434.1 (82.7) 407.4 (95.9) .91 .346 .02 
SD RT (M, SD)* 96.9 (32.3) 78.2 (28.4) 4.02 .052 .09 
Change Response MRT 
(M, SD) 
475.3 (89.7) 457.1 (71.1) 4.84 .033 .11 
Change Response SD RT 
(M, SD) 
117.0 (43.4) 113.2 (43.8) .26 .615  .01 
Note. SSRT = Stop Signal Reaction Time; MRT = mean reaction time; SD = standard 
deviation; RT = reaction time. 
* Placebo: n = 19; Methylphenidate: n = 23 (parallel trial analysis only). 
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 Figure Caption 
Figure 1. Mean Hit Reaction Time (HRT) (in ms) on CPT as a Measure of ISI and Treatment 
Condition. 
 
Figure 1 is provided in a separate file ‘Figure1.tif’.  
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Figure Caption 
Figure 2. Standard Error of Hit Reaction Time (SE HRT) (in ms) on CPT as a Measure of ISI 
and Treatment Condition. 
 
Figure 2 is provided in a separate file ‘Figure2.tif’. 
